ECE2017 Eposter Presentations: Pituitary and Neuroendocrinology Pituitary - Clinical (145 abstracts)
Gender differences in real-life GH dosing patterns in adults with GH deficiency (AGHD): experience from a Registry in France
Françoise Borson-Chazot 1 , Evguenia Hacques 2 , Véronique Pascal-Vigneron 3 , Sylvie Salenave 4 & Béatrice Villette 2
1Hôpital Louis Pradel, Bron, France; 2Novo Nordisk, La Défense, France; 3Centre Hospitalo-Universitaire Régional, Nancy, France; 4Hôpital Bicêtre, Kremlin Bicêtre, France.
Introduction: Usually GHD women require higher GH doses than males, especially those with exogenous oestrogens (guidelines). This fact was assessed in real-life practice in France.
Methods: Data were from a Registry in 84 sites treating AGHD (Norditropin®) up to 5 years. Naïve patients did not receive GH 6 months before inclusion. Statistics were descriptive.
Results: 328 patients (129 naïve) were included; mean age 49.2 years (± 14.3 S.D.). 180 were females (55%) with 72 (40%) naïve; data missing for 6. 147 (81.7%) women had a gonadotropic deficiency: 83 (79%) non-naive and 54 (75%) naive treated with oestrogen therapy. At inclusion the median IGF-1 SDS (Q1;Q3) in naive population was −2,20 (−3.20;−1.30) and in non-naïve was 0.00 (−1.30;+1.10). The median starting dose was similar for naive women and men: 0.20 mg/d. After the first year until the end of the follow up (FU) the median dose for naïve women was higher than for men. The median dose was higher for non-naive females (Table 1). At the end of the FU, the median IGF1 SDS (Q1; Q3) in naive population was +0.30 (−0.50;+0.80) and in non-naïve was +0.50 (−0.40;+1.20).
Conclusion: In real life, physicians consider the recommendation of higher GH dose for AGHD women at steady state, while the starting dose remains similar in both genders. Data from this Registry is consistent with the published data from other observational studies.
| Year | ♀ naive | ♂ naive | ♀ non-naive | ♂ non-naive |
| Inclusion | 0.20 (0.20;0.30) | 0.20 (0.20;0.30) | 0.40 (0.20;0.60) | 0.30 (0.20;0.40) |
| 1 | 0.40 (0.30;0.50) | 0.30 (0.20;0.40) | 0.40 (0.30;0.70) | 0.35 (0.20;0.50) |
| 2 | 0.50 (0.30;0.60) | 0.30 (0.20;0.40) | 0.40 (0.30;0.60) | 0.40 (0.20;0.50) |
| 3 | 0.50 (0.30;0.70) | 0.39 (0.20;0.50) | 0.40 (0.30;0.60) | 0.30 (0.20;0.50) |
| 4 | 0.50 (0.40;0.70) | 0.37 (0.20;0.50) | 0.40 (0.30;0.65) | 0.40 (0.20;0.52) |
| 5 | 0.60 (0.45;0.80) | 0.40 (0.30;0.50) | 0.40 (0.30;0.70) | 0.30 (0.20;0.52) |
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more